English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Migraine is a common and disabling health problem and the primary goals of preventive treatment are to reduce attack frequency, severity, and duration. Every patient is different and there is no ‘right’ prophylactic agent. The utility of flunarizine and propranolol in migraine prophylaxis are well-known. In all trials flunarizine was equally effective with the βadrenoceptor blockers, but had a qualitatively different adverse event profile. Based on these comparative studies as well as the placebocontrolled trials (1,2), flunarizine is considered a drug of first choice in migraine prophylaxis. But in a substantial number of patients 10 to 20%, the flunarizine remains ineffective (3). The study of Pascual J et al. (4) shows that low doses of propranolol are effective in controlling serious migraine bouts in many patients (75.5%). And the study of Bassi P et al. (5) shows low doses of flunarizine are essentially effective as migraine prophylaxis while the incidence of side effects was considerably reduced in the patients treated with the lower dose. Few trials have evaluated combination of two or more drugs in the preventive treatment of migraine (6-15). The combined therapy proved to be as safe as the mono therapy. However, the optimal antimigraine combination dosage is still unknown. This study is designed to evaluate the efficacy of a fixed combination of low doses of long-acting propranolol (LAP) and flunarizine compared with a fixed combination of classical doses of longacting propranolol (LAP) and flunarizine, when the efficacy of flunarizine fails at the "classical" dose of 10 mg.

“The Efficacy Of Combined Low-Doses Of Propranolol And Flunarizine In Episodic Migraine”